糖尿病予防と治療のエビデンス

出版社： 中山書店
著者：
発行日： 2012-05-30
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784521733807
電子書籍版： 2012-05-30 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,480 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,480 円(税込)

購入する

商品紹介

患者数の増加により，世界レベルでも問題となっている糖尿病について，診療の根拠となる国内外の臨床研究･疫学研究を簡潔に解説。病態・検査・治療法など，糖尿病のあらゆる側面から丁寧にレビューし，克服すべき「糖尿病」の本質を見極めるための有益な情報が多く盛り込まれた，臨床家必携の書。

目次

  • 糖尿病予防と治療のエビデンス

    ―目次―

    1章　エビデンスとは何か？
    2章　糖尿病の疫学
    3章　糖尿病の成因と病態に関するエビデンス
    4章　糖尿病の検査―診断・合併症予測因子としてのエビデンス
    5章　糖尿病の予防
    6章　糖尿病の治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 エビデンスとは何か ?

P.15 掲載の参考文献
1) Hemkens LG, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues : a cohort study. Diabetelogia 2009 ; 52 : 1732-44.
 
2) Pocock SJ, Smeeth L. Insulin glargine and malignancy : an unwarranted alarm. Lancet 2009 ; 374 : 511-2.
PubMed
3) ICH efficacyガイドライン. http://www.pmda.go.jp/ich/efficacy.htm
 
4) 大橋靖雄, 荒川義弘監. 臨床試験の進め方. 南江堂 : 2006.
 
5) 循環器疫学データベース. http://epi-c.jp/
 
6) Nakamura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 2006 ; 368 : 1155-63.
PubMed
7) 大橋靖雄. 治療エビデンスをいかに評価するか. 最新医学 2008 ; 63 : 193-210.
Medical*Online
8) EQUATOR Network. http://www.equator-network.org/home/
 
9) CONSORT声明/QUOROM声明/MOOSE声明関連日本語版. http://homepage3.nifty.com/cont/CONSORT_Statement/menu.html
 
10) がんのリスクの大きさ. http://www.ncc.go.jp/jp/shinsai/pdf/cancer_risk.pdf
 
11) Inoue M, et al. Diabetes mellitus and risk of cancer : results from a large-scale population-based cohort study in Japan. Arch Inter Med 2006 ; 166 : 1871-7.
 
P.21 掲載の参考文献
1) University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes I. Design, methods and baseline results, II. Mortality results. Diabetes 1970 ; 19 (Suppl 2) : 747-83, 789-830.
 
2) University Group Diabetes Program. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976 ; 25 : 1129-53.
 
3) University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1974 ; 24 (Suppl 1) : 65-184.
 
4) Edwards CC. Oral hypoglycemic agents. Report of the food and drug administration. Diabetes 1970 ; 19 (Suppl 2) : viii-ix.
 
5) Report of the Committee for the assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. JAMA 1975 ; 231 : 583-608.
 
6) Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972 ; 21 : 976-9.
PubMed
7) Kilo C, et al. The crux of the UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 1980 ; 18 : 179-85.
PubMed
8) Tattersall R. Diabetes : The Biography. Oxford Univ Press ; 2009. pp.131-5.
 
9) 日本糖尿病学会理事会. トルブタマイドに関する最近の問題について. 糖尿病 1970 ; 13 : 417.
 
10) 平田幸正. 糖尿病経口薬の意義とその問題点. 糖尿病学の進歩. 第10集. 診断と治療社 ; 1976, pp.191-202.
 
・ 小坂樹徳ほか. 経口糖尿病薬の功罪 (パネル). 日本糖尿病学会編. 糖尿病学の進歩. 第5集. 診断と治療社 ; 1971. pp.205-31.
 

2章 糖尿病の疫学

P.30 掲載の参考文献
1) International Diabetes Federation. Diabetes Atlas, 5th ed. 2011.
 
2) Patterson CC, et al ; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20 : a multicentre prospective registration study. Lancet 2009 ; 373 : 2027-33.
 
3) Craig ME, et al. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 2009 ; 10 (Suppl 12) : 3-12.
 
4) DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 2006 ; 23 : 857-66.
PubMed
5) Urakami T, et al. Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area. Diabetes Res Clin Pract 2008 ; 80 : 473-6.
PubMed
6) Matsuura N, et al. Descriptive epidemiology of IDDM in Hokkaido, Japan : the Childhood IDDM Hokkaido Registry. Diabetes Care 1998 ; 21 : 1632-6.
PubMed
7) Kida K, et al. Incidence of Type 1 diabetes mellitus in children aged 0-14 in Japan, 1986-1990, including an analysis for seasonality of onset and month of birth : JDS study. The Data Committee for Childhood Diabetes of the Japan Diabetes Society (JDS). Diabet Med 2000 ; 17 : 59-63.
 
8) Kawasaki E, et al. Type 1 diabetes in Japan. Diabetologia 2006 ; 49 : 828-36.
PubMed
9) Kyvik KO, et al. The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 2004 ; 47 : 377-84.
 
10) Major cross-country differences in risk of dying for people with IDDM. Diabetes Epidemiology Research International Mortality Study Group. Diabetes Care 1991 ; 14 : 49-54.
 
P.39 掲載の参考文献
1) Whiting DR, et al. IDF diabetes atlas : global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011 ; 94 : 311-21.
PubMed
2) IDF Diabetes atlas, 5th ed. cInternational Diabetes Federation, 2011. http://www.diabetesatlas.com/
 
3) Wild S, et al. Global prevalence of diabetes : estimates for the year 2000 and projections for 2030. Diabetes Care 2004 ; 27 : 1047-53.
PubMed
4) Wild S, et al. Global Burden of Diabetes Mellitus in the Year 2000. http://www.who.int/healthinfo/statistics/bod_diabetes.pdf
 
5) Engberg S, et al. Progression to impaired glucose regulation and diabetes in the population-based Inter99 study. Diabetes Care 2009 ; 32 : 606-11.
PubMed
6) 厚生労働省. 平成19年国民健康・栄養調査報告. http://www.mhlw.go.jp/houdou/2008/12/h1225-5.html
 
7) 厚生労働省. 平成21年国民健康・栄養調査報告. p.102. http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h21-houkoku-01.pdf
 
8) 健康日本21最終評価 ; 2011. http://www.mhlw.go.jp/stf/houdou/2r9852000001r5gcatt/2r9852000001r5np.pdf
 
9) Noda M, et al. Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study-suggestion for the threshold for impaired fasting glucose among Japanese. Endocrine Journal 2010 ; 57 : 631-9.
 
10) Kato M, et al. Fasting plasma glucose and incidence of diabetes-implication for the threshold for impaired fasting glucose : results from the population-based Omiya MA cohort study. J Atheroscler Thromb 2009 ; 16 : 857-61.
PubMed
11) 健康日本21. 健康日本21企画検討会・健康日本21計画策定検討会報告書. 健康・体力づくり事業財団 ; 2001. pp.137-145.
 
P.46 掲載の参考文献
1) Yokoyama H, et al. Microalbuminuria is common in Japanese type 2 diabetic patients : a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care 2007 ; 30 : 989-92.
 
2) Araki S, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005 ; 54 : 2983-7.
PubMed
3) de Galan BE, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009 ; 20 : 883-92.
PubMed
4) Katayama S, et al. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 1025-31.
PubMed
5) 猪股茂樹ほか. 糖尿病性腎症の新しい診断基準. 糖尿病 2005 ; 48 : 757-9.
 
6) Parving HH, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients : a global perspective. Kidney Int 2006 ; 69 : 2057-63.
 
7) de Boer IH, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011 ; 305 : 2532-9.
PubMed
8) Sorensen VR, et al. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 2006 ; 70 : 187-91.
PubMed
9) Pavkov ME, et al. Increasing incidence of proteinuria and declining incidence of end -stage renal disease in diabetic Pima Indians. Kidney Int 2006 ; 70 : 1840-6.
PubMed
10) Burrows NR, et al. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010 ; 33 : 73-7.
 
11) Maeda S, et al. Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 2010 ; 59 : 2075-9.
PubMed
・ Orchard TJ, et al. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population : a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010 ; 53 : 2312-9.
PubMed
P.52 掲載の参考文献
1) 船津英陽ほか. 糖尿病眼合併症の有病率と全身因子. 日眼会誌 1993 ; 97 : 947-54.
 
2) 高橋義彦, 野田光彦. 糖尿病網膜症の疫学とリスクファクター. 内分泌・糖尿病科 2009 ; 28 : 188-95.
 
3) 安田美穂 : 久山町研究. あたらしい眼科 2011 ; 28 : 25-9.
Medical*Online
4) 川崎良. 糖尿病網膜症-舟形町スタディ. 日本の眼科 2008 ; 79 : 1697-701.
 
5) 川崎良. 世界の疫学研究-先進国編. あたらしい眼科 2011 ; 28 : 41-7.
Medical*Online
6) Sone H, et al ; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
 
7) Stratton IM, et al. UKPDS 50 : risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001 ; 44 : 156-63.
PubMed
8) Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy : XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008 ; 115 : 1859-68.
PubMed
P.60 掲載の参考文献
1) Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997 ; 46 (Suppl 2) : S54-7.
 
2) Tesfaye S, et al. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 ; 33 : 2285-93.
PubMed
3) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害の簡易診断基準. 末梢神経 1998 ; 9 : 137-40.
 
4) 佐藤譲ほか. 糖尿病神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義-東北地方15,000人の実態調査. 糖尿病 2007 ; 50 : 799-806.
 
5) Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999 ; 7 : 245-52.
 
6) 糖尿病性神経障害を考える会. 簡易診断基準をもとにした糖尿病性多発神経障害の病期分類の公表にあたって. Peripheral Nerve 2010 ; 21 : 372-3.
 
7) Dyck PJ, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort : the Rochester Diabetic Neuropathy Study. Neurology 1993 ; 43 : 817-24.
 
・ Yagihashi S, et al. Mechanism of diabetic neuropathy : Where are we now and where to go? J Diabetes Invest 2011 ; 2 : 18-32.
 
・ Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Invest 2011 ; 2 : 33-42.
 
P.65 掲載の参考文献
1) 内村功, 渥美義仁監訳. インターナショナル・コンセンサス糖尿病足病変. 医歯薬出版 ; 2000.
 
2) Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain : a nationwide primary care diabetes clinic-based study. Ann Saudi Med 2007 ; 27 : 25-31.
PubMed
3) Reid KS, et al. Diabetic foot complications in a northern Canadian Aboriginal community. Foot Ankle Int 2006 ; 27 : 1065-73.
 
4) Abbott CA, et al. The North-West Diabetes Foot Care Study : incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002 ; 19 : 377-84.
 
5) Kumar S, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients : a population-based study. Diabet Med 1994 ; 11 : 480-4.
PubMed
6) Muller IS, et al. Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. Diabetes Care 2002 ; 25 : 570-4.
PubMed
7) Ramsey SD, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999 ; 22 : 382-7.
PubMed
8) Moss SE, et al. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992 ; 152 : 610-6.
 
9) Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996 ; 13 (Suppl 1) : S6-11.
 
10) Peters EJ, et al ; International Working Group on the Diabetic Foot. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care 2001 ; 24 : 1442-7.
 
11) Lee JS, et al. Lower-extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. Diabetes 1993 ; 42 : 876-82.
PubMed
12) Deerochanawong C, et al. A survey of lower limb amputation in diabetic patients. Diabet Med 1992 ; 9 : 942-6.
PubMed
13) Ebskov B, Josephsen P. Incidence of reamputation and death after gangrene of the lower extremity. Prosthet Orthot Int 1980 ; 4 : 77-80.
PubMed
14) Boyko EJ, et al. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996 ; 13 : 967-72.
PubMed
15) Nabuurs-Franssen MH, et al. Health-related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia 2005 ; 48 : 1906-10.
PubMed
16) Kinmond K, et al. 'Loss of self ' : a psychosocial study of the quality of life of adults with diabetic foot ulceration. J Tissue Viability 2003 ; 13 : 6-8, 10, 12 passim.
 
17) Hjelm K, et al. Gender influences beliefs about health and illness in diabetic subjects with severe foot lesions. J Adv Nurs 2002 ; 40 : 673-84.
PubMed
18) Meijer JW, et al. Quality of life in patients with diabetic foot ulcers. Disabil Rehabil 2001 ; 23 : 336-40.
PubMed
19) Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complications 2000 ; 14 : 235-41.
PubMed
20) Brod M. Quality of life issues in patients with diabetes and lower extremity ulcers : patients and care givers. Qual Life Res 1998 ; 7 : 365-72.
PubMed
21) Carrington AL, et al. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996 ; 32 : 19-25.
PubMed
22) Ragnarson Tennvall G, et al. The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. J Intern Med 2000 ; 248 : 397-405.
PubMed
23) Harrington C, et al. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000 ; 23 : 1333-8.
 
24) Van Acker K, et al. Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. Diabetes Res Clin Pract 2000 ; 50 : 87-95.
 
25) Mehta SS, et al. Determining an episode of care using claims data. Diabetic foot ulcer. Diabetes Care 1999 ; 22 : 1110-5.
PubMed
26) Holzer SE, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998 ; 20 : 169-81.
PubMed
27) Apelqvist J, et al. Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation. J Intern Med 1994 ; 235 : 463-71.
 
28) Palmer AJ, et al. The cost-effectiveness of different management strategies for type I diabetes : a Swiss perspective. Diabetologia 2000 ; 43 : 13-26.
PubMed
29) Ashry HR, et al. Cost of diabetes-related amputations in minorities. J Foot Ankle Surg 1998 ; 37 : 186-90.
PubMed
30) Panayiotopoulos YP, et al. Results and cost analysis of distal [crural/pedal] arterial revascularisation for limb salvage in diabetic and non-diabetic patients. Diabet Med 1997 ; 14 : 214-20.
PubMed
31) Singh S, et al. The costs of managing lower limb-threatening ischaemia. Eur J Vasc Endovasc Surg 1996 ; 12 : 359-62.
PubMed
32) Eckman MH, et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA 1995 ; 273 : 712-20.
PubMed
33) van Houtum WH, et al. The costs of diabetes-related lower extremity amputations in the Netherlands. Diabet Med 1995 ; 12 : 777-81.
PubMed
34) Gupta SK, et al. Cost factors in limb-threatening ischaemia due to infrainguinal arteriosclerosis. Eur J Vasc Surg 1988 ; 2 : 151-4.
PubMed
35) Ragnarson Tennvall G, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin Infect Dis 2004 ; 39 (Suppl 2) : S132-9.
 
36) Apelqvist J, et al. Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int 1995 ; 16 : 388-94.
 
37) Kuzuya T, et al. Prevalence of chronic complications in Japanese diabetic patients. Diabetes Res Clin Pract 1994 ; 24 (Suppl) : S159-64.
 
38) 厚生労働省. 平成19年国民健康・栄養調査結果の概要. Retrieved May 19, 2011. (http://www.mhlw.go.jp/houdou/2008/12/h1225-5a.html)
 
P.72 掲載の参考文献
1) Takii T, et al. MIYAGI-AMI Study Investigators. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 2010 ; 74 : 93-100.
 
2) Satoh H, et al. Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitus. Heart 2005 ; 91 : 731-6.
PubMed
3) Haffner SM, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 ; 339 : 229-34.
PubMed
4) Juutilainen A, et al. Type 2 diabetes as a "coronary heart disease equivalent" : an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005 ; 28 : 2901-7.
PubMed
5) Malmberg K, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction : results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000 ; 102 : 1014-9.
PubMed
6) Sone H, et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005 ; 28 : 1463-71.
PubMed
7) Doi Y, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 2010 ; 41 : 203-9.
 
8) Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ 2000 ; 321 : 405-12.
PubMed
9) Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology : Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999 ; 354 : 617-21.
 
10) Tominaga M, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999 ; 22 : 920-4.
 
P.80 掲載の参考文献
1) Doi Y, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 2010 ; 41 : 203-9.
 
2) Urabe T, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 2009 ; 40 : 1289-95.
PubMed
3) Cordonnier C, et al. Spontaneous brain microbleeds : systematic review, subgroup analyses and standards for study design and reporting. Brain 2007 ; 130 : 1988-2003.
PubMed
4) Lovelock CE, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage : a systematic review of published and unpublished studies. Stroke 2010 ; 41 : 1222-8.
PubMed
5) Feigin VL, et al. Risk factors for subarachnoid hemorrhage : an updated systematic review of epidemiological studies. Stroke 2005 ; 36 : 2773-80.
PubMed
6) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
7) Cholesterol Treatment Trialists' (CTT) Collaborators, et al. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins : a meta-analysis. Lancet 2008 ; 371 : 117-25.
PubMed
8) Boussageon R, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes : meta-analysis of randomised controlled trials. BMJ 2011 ; 343 : d4169.
PubMed
9) Shinohara Y, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008 ; 26 : 63-70.
PubMed
P.86 掲載の参考文献
1) Inoue M, et al. Diabetes mellitus and the risk of cancer : results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006 ; 166 : 1871-7.
PubMed
2) Inoue M, et al. Impact of metabolic factors on subsequent cancer risk : results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009 ; 18 : 240-7.
PubMed
3) Jee SH, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005 ; 293 : 194-202.
PubMed
4) Huxley R, et al. Type-II diabetes and pancreatic cancer : a meta-analysis of 36 studies. Br J Cancer 2005 ; 92 : 2076-83.
PubMed
5) El-Serag HB, et al. The association between diabetes and hepatocellular carcinoma : a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006 ; 4 : 369-80.
PubMed
6) Larsson SC, et al. Diabetes mellitus and risk of colorectal cancer : a meta-analysis. J Natl Cancer Inst 2005 ; 97 : 1679-87.
PubMed
7) Larsson SC, et al. Diabetes mellitus and risk of breast cancer : a meta-analysis. Int J Cancer 2007 ; 121 : 856-62.
PubMed
8) Friberg E, et al. Diabetes mellitus and risk of endometrial cancer : a meta-analysis. Diabetologia 2007 ; 50 : 1365-74.
PubMed
9) Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006 ; 15 : 2056-62.
 
10) Calle EE, Kaaks R. Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004 ; 4 : 579-91.
PubMed
P.91 掲載の参考文献
1) 健康日本21ホームページ. http://www.kenkounippon21.gr.jp/
 
2) Sano H, et al ; Diabetes Epidemiology Research International Study Group. Blindness and laser photocoagulation in patients with childhood-onset type 1 diabetes in Japan. Br J Ophthalmol 2009 ; 93 : 726-30.
 
3) 糖尿病ネットワークホームページ. http://www.dm-net.co.jp/calendar/2011/011746.php
 
4) Yazaki Y, Kadowaki T. Combating diabetes and obesity in Japan. Nat Med 2006 ; 12 : 73-4.
PubMed
5) 糖尿病における失明, 歯周病, 腎症, 大血管合併症などの実態把握とその治療に関するデータベース構築による大規模前向き研究. 平成21年度～22年度総合研究報告書 <厚生労働科学研究費補助金 循環器疾患・糖尿病等生活習慣病対策総合研究事業>, 研究代表者田嶼尚子. 2011.
 

3章 糖尿病の成因と病態に関するエビデンス

P.99 掲載の参考文献
1) Sone H, et al ; Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003 ; 361 : 85.
 
2) 山根公則ほか. 日本人と環境因子 : 日本人と在米日系人の生活習慣病-糖尿病, 高脂血症, 動脈硬化. 最新医学 2002 ; 57 (3月増刊号) : 689-98.
 
3) DeFronzo RA. Lilly lecture 1987. The triumvirate : beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988 ; 37 : 667-87.
PubMed
4) 清野裕. 糖尿病の新しい概念. 最新医学 1995 ; 50 (臨増) : 639-45.
 
5) Fukushima M, et al. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004 ; 66 (Suppl 1) : S37-43.
 
6) DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function : the key to Diabetes prevention. J Clin Endocrinol Metab 2011 ; 96 : 2354-66.
 
7) Seino Y, et al. GIP and GLP-1, the two incretin hormones : similarities and differences. J Diabetes Invest 2010 ; 1 : 8-23.
 
8) Vilsboll T, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003 ; 88 : 2706-13.
PubMed
9) Yabe D, et al. Little enhancement of meal-induced GLP-1 secretion in Japanese : Comparison of type 2 diabetes, and healthy controls. J Diabetes Invest 2010 ; 1 : 56-9.
 
10) Ryskjaer J, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA1c levels, but not acutely affected by food intake. Eur J Endocrinol 2006 ; 155 : 485-93.
 
11) Lee S, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2010 ; 57 : 119-26.
 
12) Lynn FC, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker ras. Diabetes 2001 ; 50 : 1004-11.
 
13) Hojberg PV, et al. Four weeks of near-normalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic peptide in patients with type 2 diabetes. Diabetologia 2009 ; 52 : 199-207.
PubMed
P.106 掲載の参考文献
1) Fukusima M, et al. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004 ; 66 (Suppl 1) : S37-43.
 
2) Chiu KC, et al. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care 2000 ; 23 : 1353-8.
PubMed
3) Raji A, et al. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001 ; 86 : 5366-71.
PubMed
4) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
PubMed
5) Dormandy JA, et al ; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 2005 ; 366 : 1279-89.
PubMed
6) Mazzone T, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes : a randomized trial. JAMA 2006 ; 296 : 2572-81.
PubMed
7) DeFronzo RA, et al ; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011 ; 364 : 1104-15.
PubMed
8) Hara K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002 ; 51 : 536-40.
PubMed
9) Nakanishi S, et al. A comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese : the impact of lifestyle westernization on diabetes mellitus. Biomed Pharmacother 2004 ; 58 : 571-7.
PubMed
10) Watson GS, et al. Effects of exercise and nutrition on memory in Japanese Americans with impaired glucose tolerance. Diabetes Care 2006 ; 29 : 135-6.
PubMed
P.112 掲載の参考文献
1) Kadowaki T, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984 ; 26 : 44-9.
PubMed
2) Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999 ; 22 : 1266-72.
PubMed
3) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
PubMed
4) Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 ; 344 : 1343-50.
PubMed
5) Kosaka K, et al. Prevention of type 2 diabetes by lifestyle intervention : a Japanese trial in IGT males. Diabetes Res Clin Pract 2005 ; 67 : 152-62.
PubMed
6) Sakane N, et al. Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011 ; 11 : 40.
 
7) Wang Y, et al. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005 ; 81 : 555-63.
PubMed
8) Hu D, et al. Central rather than overall obesity is related to diabetes in the Chinese population : the InterASIA study. Obesity 2007 ; 15 : 2809-16.
PubMed
9) 厚生労働省健康科学総合研究事業. 糖尿病発症高危険群におけるインスリン抵抗性とその生活習慣基盤に関する多施設共同追跡調査-介入対象としての内臓肥満の意義の確立 (主任研究者松澤佑次) 総合研究報告書. 2001.
 
P.120 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 2005 ; 94 : 794-809.
 
2) Alberti KG, et al ; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide defi nition. Lancet 2005 ; 366 : 1059-62.
 
3) Hiuge-Shimizu A, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med 2012 ; 44 : 82-92.
PubMed
4) Miyawaki T, et al. Metabolic syndrome in Japanese diagnosed with visceral fat measurement by computed tomography. Proc Japan Acad 2005 ; 81 : 471-9.
 
5) Oka R, et al. Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract 2008 ; 79 : 474-81.
PubMed
6) Balkau B, et al. International Day for the Evaluation of Abdominal Obesity (IDEA) : a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007 ; 116 : 1942-51.
PubMed
7) Alberti KG, et al. Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention ; National Heart, Lung, and Blood Institute ; American Heart Association ; World Heart Federation ; International Atherosclerosis Society ; and International Association for the Study of Obesity. Circulation 2009 ; 120 : 1640-5.
 

4章 糖尿病の検査 - 診断・合併症予測因子としてのエビデンス

P.129 掲載の参考文献
1) 葛谷健. 糖尿病の新しい診断基準日本および世界の糖尿病の診断基準の変遷-2000年まで. 内分泌・糖尿病・代謝内科 2011 ; 32 : 4-9.
 
2) 葛谷健ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 1999 ; 42 : 385-404.
 
3) American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010 ; 33 (Suppl 1) : S62-9.
 
4) World Health Organizationa. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation ; 2011.
 
5) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
・ 小坂樹徳, 門脇 孝. 糖尿病診療のあゆみと展望. 文光堂 ; 2007.
 
P.135 掲載の参考文献
1) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
2) 門脇孝ほか. 糖尿病・糖代謝異常に関する診断基準検討委員会報告-空腹時血糖値の正常域に関する新区分. 糖尿病 2008 ; 51 : 281-3.
 
3) 日本糖尿病学会編. 治療目標とコントロール指標. 糖尿病治療ガイド 2010. 文光堂 ; 2010. pp.24-5.
 
P.140 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes control and complications trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
4) The International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009 ; 32 : 1327-34.
 
5) Hoelzel W, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden : a method-comparison study. Clin Chem 2004 ; 50 : 166-74.
PubMed
P.146 掲載の参考文献
1) Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010 ; 57 : 751-62.
PubMed
2) Sakuma N, et al. Converse contributions of fasting and postprandial glucose to HbA1c and glycated albumin. Diabetol Int 2011 ; 2 : 162-71.
 
3) Koga M, et al. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care 2010 ; 33 : 270-2.
PubMed
4) Yoshiuchi K, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J 2008 ; 55 : 503-7.
PubMed
5) Koga M, et al. Glycated albumin levels are higher relative to HbA1c levels in people with autoimmune acute-onset type 1 diabetes mellitus than in people with type 2 diabetes mellitus at the time of diagnosis. Diabetes Res Clin Pract 2011 ; 94 : e12-4.
PubMed
6) Koga M, et al. Serum glycated albumin to haemoglobin A1C ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Ann Clin Biochem 2010 ; 47 : 313-7.
PubMed
7) Furusyo N, et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study : results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 2011 ; 54 : 3028-36.
 
8) Lu L, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-α with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007 ; 40 : 810-6.
 
9) Freedman BI, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011 ; 6 : 1635-43.
PubMed
10) Selvin E, et al. Nontraditional markers of glycemia : associations with microvascular conditions. Diabetes Care 2011 ; 34 : 960-7.
PubMed
P.152 掲載の参考文献
1) Yamanouchi T, et al. Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism 1992 ; 41 : 862-7.
PubMed
2) Kishimoto M, et al. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995 ; 18 : 1156-9.
PubMed
3) Dungan KM, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006 ; 29 : 1214-9.
PubMed
4) Nonaka K, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 ; 79 : 291-8.
PubMed
5) Yamanouchi T, et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 1992 ; 263 : E268-73.
 
6) Ohira M, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 2011 ; 60 : 78-85.
PubMed
・ Yamanouchi T. Glycemic stability in patients with diabetes mellitus-a new therapeutic goal and new glycemic marker, 1,5-AG. Nova Science Publishers ; 2009. pp.271-82.
 
・ 山内俊一. 1,5-アンヒドログルシトールと食後高血糖. Diabetes Frontier 2010 ; 21 : 154-8.
Medical*Online
P.158 掲載の参考文献
1) Nathan DM, et al ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008 ; 31 : 1473-8.
 
2) Del Prato S. In search of normoglycaemia in diabetes : controlling postprandial glucose. Int J Obes Relat Metab Disord 2002 ; 26 (Suppl 3) : S9-17.
 
3) Boyne MS, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003 ; 52 : 2790-4.
PubMed
4) Cheyne EH, et al. Performance of a continuous glucose monitoring system during controlled hypoglycaemia in healthy volunteers. Diabetes Technol Ther 2002 ; 4 : 607-13.
PubMed
5) Wolpert HA. Use of continuous glucose monitoring in the detection and prevention of hypoglycemia. J Diabetes Sci Technol 2007 ; 1 : 146-50.
PubMed
6) http://wwwp.medtronic.com/newsroom/content/1100187878655.low_resolution.jpg
 
7) 西村理明. CGM-持続血糖モニターが切り開く世界. 改訂版. 医薬ジャーナル社 ; 2011.
 
8) Di Flaviani A, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 2011 ; 34 : 1605-9.
PubMed
9) Su G, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011 ; 10 : 19.
 
10) Service FJ, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970 ; 19 : 644-55.
 

5章 糖尿病の予防

P.166 掲載の参考文献
1) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
PubMed
2) Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP) : description of lifestyle intervention. Diabetes Care 2002 ; 25 : 2165-71.
 
3) Look Ahead Research Group, et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 2006 ; 3 : 202-15.
 
4) Look AHEAD Research Group, et al. The Look AHEAD study : a description of the lifestyle intervention and the evidence supporting it. Obesity 2006 ; 14 : 737-52.
 
5) Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus : four-year results of the Look AHEAD trial. Arch Intern Med 2010 ; 170 : 1566-75.
 
P.174 掲載の参考文献
1) 伊藤千賀子ほか. 血糖の指標と糖尿病発症. medicina 2010 ; 47 : 1910-3.
 
2) Heianza Y, et al. HbA1c 5・7-6・4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3) : a longitudinal cohort study. Lancet 2011 ; 378 : 147-55.
 
3) Nakagami T, et al. Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia 2003 ; 46 : 1063-70.
PubMed
4) Okada K, et al. Leisure-time physical activity at weekends and the risk of Type 2 diabetes mellitus in Japanese men : the Osaka Health Survey. Diabet Med 2000 ; 17 : 53-8.
PubMed
5) Mizoue T, et al. Dietary patterns and glucose tolerance abnormalities in Japanese men. J Nutr 2006 ; 136 : 1352-8.
 
6) Willi C, et al. Active smoking and the risk of type 2 diabetes : a systematic review and meta-analysis. JAMA 2007 ; 298 : 2654-64.
PubMed
7) Yeh HC, et al. Smoking, smoking cessation, and risk for type 2 diabetes mellitus : a cohort study. Ann Intern Med 2010 ; 152 : 10-7.
PubMed
8) 石田さくらこほか. 生活習慣介入による糖尿病一次予防 (The Diabetes Prevention Program of Hiroshima ; DPPH). 糖尿病 2004 ; 47 : 707-13.
 
9) Sakane N, et al. Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011 ; 11 : 40.
 
10) Kosaka K, et al. Prevention of type 2 diabetes by lifestyle intervention : a Japanese trial in IGT males. Diabetes Res Clin Pract 2005 ; 67 : 152-62.
PubMed
11) 坂根直樹ほか. 2型糖尿病発症予防のための介入試験-J-DOIT1. Diabetes Frontier 2008 ; 19 : 638-42.
Medical*Online
・ Yamaoka K, Tango T. Effi cacy of lifestyle education to prevent type 2 diabetes : a meta-analysis of randomized controlled trials. Diabetes Care 2005 ; 28 : 2780-6.
 
P.180 掲載の参考文献
1) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
PubMed
2) Knowler WC, et al ; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 ; 54 : 1150-6.
 
3) Buchanan TA, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002 ; 51 : 2796-803.
 
4) Xiang AH, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 ; 55 : 517-22.
 
5) DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose : a randomised controlled trial. Lancet 2006 ; 368 : 1096-105.
PubMed
6) DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators, et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011 ; 54 : 487-95.
PubMed
7) DeFronzo RA, et al ; ACT NOW Study. Pioglitzaone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011 ; 364 : 1104-15.
PubMed
8) Dormandy JA, et al ; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 2005 ; 366 : 1279-89.
PubMed
P.186 掲載の参考文献
1) Kawamori R. Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract 1998 ; 40 (Suppl) : S35-42.
 
2) Kawamori R, et al. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 ; 373 : 1607-14.
PubMed
3) Tamura Y, et al. Effects of diet an d exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005 ; 90 : 3191-6.
 
4) DeFronzo RA, et al ; ACT NOW Study Group. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010 ; 53 : 435-45.
 
5) Sato F, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007 ; 92 : 3326-9.
PubMed
6) Scheen AJ. Voglibose for prevention of type 2 diabetes mellitus. Lancet 2009 ; 373 : 1579-80.
PubMed
7) Arakawa M, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008 ; 57 : 1299-306.
PubMed
P.194 掲載の参考文献
1) DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulindependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995 ; 333 : 541-9.
 
2) Cho YM, Kieffer TJ. New aspects of an old drug : metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011 ; 54 : 219-22.
PubMed
3) Schernthaner G, et al ; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus : a doubleblind, randomized trial. J Clin Endocrinol Metab 2004 ; 89 : 6068-76.
 
4) Reasner C, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011 ; 13 : 644-52.
PubMed
5) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
PubMed
6) Nathan DM, et al ; American Diabetes Association ; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 ; 32 : 193-203.
 
7) Rodbard HW, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus : an algorithm for glycemic control. Endocr Pract 2009 ; 15 : 540-59.
 
8) Qaseem A, et al. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus : A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2012 ; 156 : 218-31.
PubMed
9) 加来浩平ほか. 2型糖尿病患者におけるメトホルミンの使用実態に関する観察研究 (MORE study). 糖尿病 2006 ; 49 : 325-31.
 
10) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
11) van Berlo-van de Laar IR, et al. Metformin associated lactic acidosis : incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011 ; 36 : 376-82.
PubMed
P.201 掲載の参考文献
1) NAVIGATOR Study Group, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1463-76.
 
2) NAVIGATOR Study Group, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1477-90.
 
3) Saloranta C, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002 ; 25 : 2141-6.
 
4) Chiasson JL, et al ; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 2003 ; 290 : 486-94.
 
P.206 掲載の参考文献
1) Tuomilehto J, et al ; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 ; 344 : 1343-50.
 
2) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
PubMed
3) Sakane N, et al ; Japan Diabetes Prevention Program (JDPP) Research Group. Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011 ; 11 : 40.
 
4) Hernan WH, et al ; Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003 ; 26 : 36-47.
 

6章 糖尿病の治療

P.212 掲載の参考文献
1) Peeples M, et al. The conceptual framework of the National Diabetes Education Outcomes System (NDEOS). Diabetes Educ 2001 ; 27 : 547-62.
PubMed
2) Funnell MM, et al. National standards for diabetes self-management education. Diabetes Care 2010 ; 33 (Suppl 1) : S89-96.
 
3) Anderson RM, et al. Evaluating the Efficacy of an Empowerment-Based Self-Management Consultant Intervention : Results of a Two-Year Randomized Controlled Trial. Ther Patient Educ 2009 ; 1 : 3-11.
PubMed
4) Polonsky WH, et al. Assessment of diabetes-related distress. Diabetes Care 1995 ; 18 : 754-60.
PubMed
5) Winkley K, et al. Psychological interventions to improve glycaemic control in patients with type 1 diabetes : systematic review and meta-analysis of randomised controlled trials. BMJ 2006 ; 333 : 65-9.
PubMed
6) Ismail K, et al. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004 ; 363 : 1589-97.
PubMed
7) 日本糖尿病学会編. 糖尿病治療ガイド 2010. 文光堂 ; 2010. p.33.
 
8) 矢部大介ほか. 糖尿病カンバセーション・マップ(TM) を用いた療養指導の有用性 : 質問紙を用いた検討. 日本病態栄養学会誌 2010 ; 13 : 329-37.
Medical*Online
P.220 掲載の参考文献
1) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010.
 
2) Klein S, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes : rationale and strategies : a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004 ; 27 : 2067-73.
 
3) Pijls LT, et al. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus : a randomized trial. Eur J Clin Nutr 2002 ; 56 : 1200-7.
PubMed
4) Anderson JW, et al. Carbohydrate and fiber recommendations for individuals with diabetes : a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr 2004 ; 23 : 5-17.
PubMed
5) Institute of Medicine : Dietary Reference Intakes : Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC ; National Academies Press, 2002.
 
6) Kodama S, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes : a meta-analysis. Diabetes Care 2009 ; 32 : 959-65.
PubMed
7) Gardner CD, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women : the A TO Z Weight Loss Study : a randomized trial. JAMA 2007 ; 297 : 969-77.
 
8) Chandalia M, et al. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000 ; 342 : 1392-8.
PubMed
9) American Dietetic Association. Nutrition Recommendation and Interventions for Diabetes. 2008.
 
10) Raben A, et al. Diurnal metabolic profiles after 14d of an ad libitum high-starch, high-sucrose, or high-fat diet in normal-weight never-obese and postobese women. Am J Clin Nutr 2001 ; 73 : 177-89.
PubMed
P.225 掲載の参考文献
1) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010. pp.41-9.
 
2) Colberg SR, et al. Exercise and type 2 diabetes : the American College of Sports Medicine and the American Diabetes Association : joint position statement. Diabetes Care 2010 ; 33 : e147-67.
PubMed
3) Nelson JD, et al. Metabolic response of normal man and insulin-infused diabetics to postprandial exercise. Am J Physiol 1982 ; 242 : E309-16.
PubMed
4) Tamura Y, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005 ; 90 : 3191-6.
PubMed
5) Boule NG, et al. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus. Diabetologia 2003 ; 46 : 1071-81.
PubMed
6) Levine JA, et al. Interindividual variation in posture allocation : possible role in human obesity. Science 2005 ; 307 : 584-6.
PubMed
7) Sigal RJ, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes : a randomized trial. Ann Intern Med 2007 ; 147 : 357-69.
 
P.233 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
3) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 37-53.
 
4) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
5) DCCT/EDIC Research Group, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011 ; 365 : 2366-76.
 
6) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
PubMed
7) Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
PubMed
8) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
9) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
10) Duckworth W, et al ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 ; 360 : 129-39.
PubMed
11) ACCORD Study Group, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011 ; 364 : 818-28.
 
12) Boussageon R, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes : meta-analysis of randomised controlled trials. BMJ 2011 ; 343 : d4169.
PubMed
13) Hemmingsen B, et al. Intensive glycaemic control for patients with type 2 diabetes : systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011 ; 343 : d6898.
PubMed
14) Ray KK, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus : a meta-analysis of randomised controlled trials. Lancet 2009 ; 373 : 1765-72.
PubMed
15) Kelly TN, et al. Systematic review : glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009 ; 151 : 394-403.
PubMed
16) Wright RJ, Frier BM. Vascular disease and diabetes : is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008 ; 24 : 353-63.
PubMed
17) Budnitz DS, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011 ; 365 : 2002-12.
PubMed
18) Zoungas S, et al ; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010 ; 363 : 1410-8.
 
19) Currie CJ, et al. Survival as a function of HbA (1c) in people with type 2 diabetes : a retrospective cohort study. Lancet 2010 ; 375 : 481-9.
PubMed
20) Shurraw S, et al ; Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease : a population-based cohort study. Arch Intern Med 2011 ; 171 : 1920-7.
PubMed
21) Chiasson JL, et al ; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 2003 ; 290 : 486-94.
 
22) Waden J, et al ; Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009 ; 58 : 2649-55.
 
23) Reaven PD, et al ; Veterans Affairs Diabetes Trial. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009 ; 58 : 2642-8.
PubMed
24) Greenfield S, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes : a cohort study. Ann Intern Med 2009 ; 151 : 854-60.
PubMed
25) Sone H, et al ; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
 
26) Katayama S, et al ; Japan Diabetes Complications Study Group. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 1025-31.
 
27) Kawasaki R, et al ; Japan Diabetes Complications Study Group. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes : 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 2288-94.
 
28) Sone H, et al ; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes : subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011 ; 96 : 3448-56.
 
29) Type 2 diabetes-time to change our approach. Lancet 2010 ; 375 : 2193.
PubMed
P.240 掲載の参考文献
1) Frid A, et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010 ; 36 (Suppl 2) : S3-18.
 
2) Polonsky KS, et al. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988 ; 81 : 442-8.
PubMed
3) Home PD, et al. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus : a randomized controlled trial. Diabet Med 2000 ; 17 ; 762-70.
PubMed
4) Wright A, et al ; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy : efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 ; 25 : 330-6.
 
5) Holman RR, et al ; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007 ; 357 : 1716-30.
PubMed
6) Bretzel RG, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO) : an open randomised controlled trial. Lancet 2008 ; 371 : 1073-84.
PubMed
・ 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 6インスリンによる治療. 南江堂 ; 2010 : pp.65-75.
 
P.245 掲載の参考文献
1) Kilo C, et al. The Achilles heel of the University Group Diabetes Program. JAMA 1980 ; 243 : 450-7.
PubMed
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
4) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
5) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
6) Ray KK, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus : a meta-analysis of randomised controlled trials. Lancet 2009 ; 373 : 1765-72.
PubMed
7) Gastaldelli A, et al. Beta-cell dysfunction and glucose intolerance : results from the San Antonio metabolism (SAM) study. Diabetologia 2004 ; 47 : 31-9.
 
・ 志熊淳平, 小田原雅人. 2型糖尿病の厳格血糖管理と心血管病予防の効果をみる. Vascular Med 2011 ; 7 : 15-20.
Medical*Online
P.252 掲載の参考文献
1) Zinman B, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial) : a double-blind randomised controlled study. Lancet 2010 ; 376 : 103-11.
 
2) DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulindependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995 ; 333 : 541-9.
 
3) Inzucchi SE, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998 ; 338 : 867-72.
PubMed
4) DeFronzo RA, et al ; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011 ; 364 : 1104-15.
PubMed
5) Kahn SE, et al ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 ; 355 : 2427-43.
PubMed
6) Kahn SE, et al ; ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011 ; 60 : 1552-60.
 
7) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
PubMed
8) DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose : a randomised controlled trial. Lancet 2006 ; 368 : 1096-105.
PubMed
9) Nissen SE. The DREAM trial. Lancet 2006 ; 368 : 2049.
PubMed
10) Dormandy JA, et al ; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 2005 ; 366 : 1279-89.
PubMed
11) Lincoff AM, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus : a meta-analysis of randomized trials. JAMA 2007 ; 298 : 1180-8.
PubMed
12) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
PubMed
13) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
14) Lamanna C, et al. Effect of metformin on cardiovascular events and mortality : a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011 ; 13 : 221-8.
PubMed
15) Mannucci E, et al. Pioglitazone and cardiovascular risk. A comprehensive metaanalysis of randomized clinical trials. Diabetes Obes Metab 2008 ; 10 : 1221-38.
PubMed
16) Decensi A, et al. Metformin and cancer risk in diabetic patients : a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010 ; 3 : 1451-61.
PubMed
17) Tzoulaki I, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs : retrospective cohort study using UK general practice research database. BMJ 2009 ; 339 : b4731.
PubMed
・ DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011 ; 34 (Suppl 2) : S202-9.
 
P.261 掲載の参考文献
1) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
2) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
PubMed
3) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
4) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 713-20.
Medical*Online
5) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
6) Holman RR, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 ; 359 : 1565-76.
PubMed
7) Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ 2000 ; 321 : 405-12.
PubMed
8) Adler AI, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) : prospective observational study. BMJ 2000 ; 321 : 412-9.
PubMed
9) Nathan DM, et al ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 ; 353 : 2643-53.
 
10) Stratton IM, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes : a prospective observational study (UKPDS 75). Diabetologia 2006 ; 49 : 1761-9.
PubMed
P.267 掲載の参考文献
1) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
2) Wake N, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes : a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000 ; 48 : 201-10.
PubMed
3) Shichiri M, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients. Diabetes Care 2000 ; 23 (Suppl 2) : B21-9.
 
4) 荒木栄一, 岸川秀樹 : 大規模試験から得られた発症・進展抑制のエビデンスKumamoto Study. 日本臨牀 2010 ; 68, 増刊号 9 : 114-20.
 
5) Nishikawa T, et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003 ; 26 : 1507-12.
PubMed
P.274 掲載の参考文献
1) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
2) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
3) Duckworth W, et al ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 ; 360 : 129-39.
PubMed
4) ACCORD Study Group ; ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.
 
5) Bonds DE, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes : retrospective epidemiological analysis of the ACCORD study. BMJ 2010 ; 340 : b4909.
PubMed
6) Zoungas S, et al ; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010 ; 363 : 1410-8.
 
7) Zoungas S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes : evidence of glycaemic thresholds. Diabetologia 2012 ; 55 : 636-43.
PubMed
8) Ray KK, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus : a meta-analysis of randomised controlled trials. Lancet 2009 ; 373 : 1765-72.
PubMed
P.279 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2009年版. ライフサイエンス出版 ; 2009.
 
2) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
3) Chaturvedi N, et al ; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomised, placebo-controlled trials. Lancet 2008 ; 372 : 1394-402.
 
4) Gade P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
 
P.285 掲載の参考文献
1) Haffner SM, et. al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 ; 339 : 229-34.
 
2) 上島弘嗣. NIPPON DATAからみた循環器疾患のエビデンス. 日本医事新報社 ; 2008.
 
3) Fujishima M, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan : The Hisayama Study. Diabetes 1996 ; 45 (Suppl 3) : S14-6.
 
4) 曽根博仁ほか. 日本から発信する血管病のEBM 第1回JDCS (Japan Diabetes complications Study). Vascular Medicine 2005 ; 1 : 86-94.
 
5) 清原裕. 地域住民中の糖尿病者における循環器疾患発症とその危険因子の関連久山町研究. 糖尿病合併症 2000 ; 14 : 80-4.
 
6) Tajima N, et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes : diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008 ; 199 : 455-62.
PubMed
7) Colhoun HM, et al ; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomised placebo-controlled trial. Lancet 2004 ; 364 : 685-96.
PubMed
8) Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins : a meta-analysis. Lancet 2008 ; 371 : 117-25.
PubMed
9) Oikawa S, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism : Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009 ; 206 : 535-9.
PubMed
10) ACCORD Study Group, Ginsberg HN, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.
 
11) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285 : 2486-97.
 
12) DeFaria Yeh D, Waters DD. The SPARCL study : extending the indications of statin therapy for stroke? Nat Clin Pract Cardiovasc Med 2007 ; 4 : 128-9.
PubMed
P.291 掲載の参考文献
1) Gade P, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : the Steno type 2 randomised study. Lancet 1999 ; 353 : 617-22.
 
2) Gade P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
 
3) Gade P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
 
4) Gade P, Pedersen O. Intensive integrated therapy of type 2 diabetes : implications for long-term prognosis. Diabetes 2004 ; 53 (Suppl 3) : S39-47.
 
5) ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.
 
6) Griffin SJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe) : a cluster-randomised trial. Lancet 2011 ; 378 : 156-67.
 
P.296 掲載の参考文献
1) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
PubMed
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
4) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
5) Duckworth W, et al ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 ; 360 : 129-39.
PubMed
6) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
P.300 掲載の参考文献
1) Seino Y, et al. GIP and GLP-1, the two incretin hormones : similarities and differences. J Diabet Invest 2010 ; 1 : 9-23.
 
2) Amori RE, et al. Efficacy and safety of incretin therapy in type 2 diabetes : systematic review and meta-analysis. JAMA 2007 ; 298 : 194-206.
PubMed
3) Monami M, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes : a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010 ; 20 : 224-35.
PubMed
4) Monami M, et al. Safety of dipeptidyl peptidase-4 inhibitors : a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011 ; 27 (Suppl 3) : 57-64.
 
5) Monami M, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors : evidence from randomized clinical trials. Diabetes Metab Res Rev 2011 ; 27 : 362-72.
PubMed
6) Iwasaki M, et al. Predicting efficacy of DPP-4 inhibitors in patients with type 2 diabetes : association of HbA1c reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabet Invest, in press.
 
7) Monami M, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes : a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009 ; 160 : 909-17.
PubMed
8) Bunck MC, et al. Extended, 3-year, exenatide therapy shows sustainable effects on beta cell disposition index in metformin treated patients with type 2 diabetes. Diabetes Care 2011 ; 34 : 2041-7.
 
9) Foley JE, et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia : a randomised controlled trial. Diabetologia 2011 ; 54 : 1985-91.
 
10) Tschen SI, et al. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 2009 ; 58 : 1312-20.
PubMed
11) Monami M, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events : a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011 ; 2011 : 215764.
PubMed
P.304 掲載の参考文献
1) Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology : Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999 ; 354 : 617-21.
 
2) Nakagami T ; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular diseases in five populations of Asian origin. Diabetologia 2004 ; 47 : 385-94.
 
3) Tominaga M, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. the Funagata Diabetes Study. Diabetes Care 1999 ; 22 : 920-4.
 
4) Hanefeld M, et al. Risk factors for myocardial infarction and death in newly detected NIDDM : the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 ; 39 : 1577-83.
PubMed
5) Chiasson JL, et al ; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 2003 ; 290 : 486-94.
 
6) Kawamori R, et al ; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 ; 373 : 1607-14.
 
7) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
8) ADVANCE Collaborative Group, Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
9) Duckworth W, et al ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 ; 360 : 129-39.
PubMed
10) Ismail-Beigi F, et al. Individualizing glycemic targets in type 2 diabetes mellitus : implications of recent clinical trials. Ann Intern Med 2011 ; 154 : 554-9.
PubMed
・ Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed

書評

最近チェックした商品履歴

Loading...